Rhythm Pharmaceuticals (RYTM) Insider Good Sells 4,712 Shares
Insider Jennifer Good sold 4,712 shares of Rhythm Pharmaceuticals on June 23, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jennifer Good sold 4,712 shares of Rhythm Pharmaceuticals, Inc. ($RYTM) on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RYTM is up 4.6% after 1 week, down 3.3% after 1 month and down 18.9% to date (from the $106.19 close on Jun 23, 2026).
RYTM
Rhythm Pharmaceuticals, Inc.
Key Points
- Jennifer Good sold 4,712 shares of Rhythm Pharmaceuticals (RYTM) on June 23, 2026, with the stock priced at $107.55 at the time of the transaction.
- Rhythm Pharmaceuticals has a market cap of about $6.8 billion and is currently trading near its 52-week high of $122.20.
- Analysts maintain a strong buy consensus on Rhythm Pharmaceuticals, with a target mean price of $138.59.
Get $RYTM trade alerts by text
We text you when insiders, Congress or big funds trade $RYTM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Rhythm Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.
On June 23, 2026, Jennifer Good sold 4,712 shares of Rhythm Pharmaceuticals, Inc. (RYTM) on the NasdaqGM. The shares were valued at about $507,000, based on a stock price of $107.55 at the time of the transaction. This sale is part of a broader pattern of insider activity at the company.
Recent Insider Activity
On the same day, David McGirr also sold 4,712 shares of Rhythm Pharmaceuticals. Earlier, he had purchased an equal number of shares, indicating a mix of buying and selling among insiders. Lynn Tetrault made a notable move on June 22, 2026, acquiring 37,000 shares at $28.27 each, totaling approximately $1,045,990. This recent activity may reflect varying levels of confidence among the company's insiders.
How Rhythm Pharmaceuticals, Inc. Stock Has Traded
Rhythm Pharmaceuticals is currently trading around $107.55, close to its 52-week high of $122.20. The stock has shown strong performance, particularly with a market cap of about $6.8 billion. The company's forward P/E ratio is negative, suggesting it is not currently profitable, but revenue has grown significantly, with a reported $239.9 million over the last year.
Analysts Set New Price Targets
Analysts have a positive outlook on Rhythm Pharmaceuticals. On October 15, 2026, JP Morgan maintained an overweight rating with a price target of $145. Additionally, HC Wainwright & Co. kept a buy rating with a target of $130. The consensus among analysts is strong buy, with a target mean price of $138.59 based on 17 opinions.
What Rhythm Pharmaceuticals, Inc. Does
Rhythm Pharmaceuticals focuses on rare neuroendocrine diseases and has several products in various stages of clinical trials. Its lead product, IMCIVREE, targets specific types of obesity linked to genetic disorders. The company's ongoing research and development efforts are crucial as it aims to expand its product offerings.
What's Ahead for Rhythm Pharmaceuticals, Inc.
Investors will be watching for Rhythm Pharmaceuticals' next earnings report, scheduled for November 3, 2026. With a history of insider trading activity and a strong analyst consensus, developments in the company could impact its stock performance. Note that the recent insider transactions reflect positions as of June 23, 2026, and may not represent current holdings.
Related Filing Alerts
Source: Jennifer Good's Form 4 filing on $RYTM (Jun 23, 2026). Find the original filing: RYTM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts